Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
Last Updated: Thursday, December 19, 2024
Researchers evaluated the combination of tafasitamab plus lenalidomide (TAFA-LEN) given either before or after CAR T-cell therapy in patients with large B-cell lymphoma. They found that the combination showed limited efficacy after CAR T-cell failure in high-risk populations. Survival rates were comparable between TAFA-LEN and other treatments for first progression after CAR T-cell therapy.
Advertisement
News & Literature Highlights